Pharma Company Avoids $50M Payment Obligation Over Cancer Drug

, Delaware Law Weekly

   | 0 Comments

The Delaware Court of Chancery on Wednesday ruled that drugmaker Gilead Sciences Inc. can avoid a $50 million milestone payment to shareholders of a company it bought in 2011, finding that a drug it acquired from Calistoga Pharmaceuticals Inc. did not win the kind of broad approval needed to trigger the post-closing bonus.

This premium content is reserved for Delaware Law Weekly subscribers.

Continue reading by getting started with a subscription.

Already a subscriber? Log in now

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article #1202781457795

Thank you!

This article's comments will be reviewed.